Loading company…
Siludi Medicine develops tumor immunotherapy drugs.
Founded in 2017 and based in Shanghai, China, Siludi Medicine researches, develops, and commercializes tumor immunotherapy drugs. Its clinical-stage pipeline includes KN035, a subcutaneous PD-L1 antibody, and 3D-185, an FGFR-1/2/3 inhibitor. In October 2020, it raised CNY 970 million in Series A funding from Efung Capital, China Capital Management, Tigermed, and Haide Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in